Use of ranibizumab for the treatment of subretinal neovascularization in pathologic myopia: a prospective study
A.R. Korol2, Dr Sc (Med)
1Danylo Halytsky Lviv National Medical University
2Filatov Institute of Eye Disease and Tissue Therapy, Odessa
Purpose: To determine the efficacy of ranibizumab as a treatment for subretinal neovascularization (SRNV) in pathologic myopia.
Materials and Methods: This was an uncontrolled, prospective cohort study, involving 66 pathologic myopic eyes (65 patients) with SRNV. Patients were treated with 0.05-mL (0.5 mg) intravitreal ranibizumab and followed up over 12 months. The best-corrected visual acuity (BCVA) at 12 months was used as a primary end point. Safety, OCT retinal thickness at the fovea, activity of SRNV as assessed by fluorescein angiography, and the number of ranibizumab injections were secondary end points.
Results: Compared with baseline, the visual acuity improved significantly at all follow-up points (р = 0.001). The mean BCVA was 0.2 (SD 0.13) at baseline and improved to 0.4 (SD 0.21) at month 12. The mean CRT was 313 µm (SD 82) at baseline and decreased to 244 µm (SD 31) at the end point (р = 0.0001).
Conclusions: Intravitreal ranibizumab was found to be a safe and efficacious treatment for SRNV in pathologic myopia at the follow-up of 12 months. In routine clinical practice, the use of ranibizumab for the treatment of SRNV in pathologic myopia results in a statistically significant improvement in visual acuity and a regression in retinal edema.
Key words:subretinal neovascularization, pathologic myopia, ocular disease, ranibizumab, angiogenesis inhibitors
- Tano Y. Pathologic myopia: where are we now? Am J Ophthalmol. 2002 Nov;134(5):645-60.
- Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003 Jul;110(7):1297-305.
- Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina. 1992;12(2):127-33.
- Ohno-Matsui K, Yoshida T, Futagami S et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol. 2003;87:570–3.
- Baba T, Kubota-Taniai M, Kitahashi M et al. Two-year Comparison of Photodynamic Therapy and Intravitreal Bevacizumab for Treatment of Myopic Choroidal Neovascularization. Br J Ophthalmol. 2010 Jul;94(7):864-70.
- Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology. 2001 May;108(5):841-52.
- Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration Updated findings from two clinical trials. Arch Ophthalmol. 1993 Sep;111(9):1200-9.
- Secrétan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997 Oct-Dec;7(4):307-16.
- Jalkh AE, Weiter JJ, Trempe CL et al. Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic Surg. 1987 Oct;18(10):721-5.
- Ozdek S, Hondur A, Gurelik G. et al. Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up. Int Ophthalmol. 2005 Aug-Oct;26(4-5):127-33.
- Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial FVIP report no. 3. Ophthalmology. 2003 Apr;110(4):667-73.
- Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularization in pathologic myopia. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004765.
- Arias L, Planas N, Prades A, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol. 2008 Aug;92(8):1035-9.
- Laud K, Spaide RF, Freund KB et al. Treatment of choroidal neovascularization of pathologic myopia with intravitreal bevacizumab. Retina. 2006;26:960-3.
- Ikuno Y, Sayanagi K, Soga K et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009 Jan;147(1):94-100.
- Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014 Mar;121(3):682-92.e2.